{"id":"NCT00554216","sponsor":"VIVUS LLC","briefTitle":"Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults","officialTitle":"A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI ≥ 35","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2007-11-06","resultsPosted":"2012-09-06","lastUpdate":"2012-09-10"},"enrollment":1267,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity"],"interventions":[{"type":"DRUG","name":"VI-0521","otherNames":[]},{"type":"DRUG","name":"VI-0521","otherNames":[]},{"type":"DRUG","name":"Placebo matched phentermine/topiramate","otherNames":[]}],"arms":[{"label":"VI-0521 Low","type":"EXPERIMENTAL"},{"label":"VI-0521 Top","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.","primaryOutcome":{"measure":"Percent Weight Loss From Baseline to Week 56","timeFrame":"baseline to 56 weeks","effectByArm":[{"arm":"Placebo","deltaMin":1.55,"sd":0.395},{"arm":"VI-0521 Low","deltaMin":5.1,"sd":0.538},{"arm":"VI-0521 Top","deltaMin":10.92,"sd":0.392}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["28455281"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":513},"commonTop":["upper respiratory tract infection","headache","constipation","dry mouth","paresthesia"]}}